Guardant Health (GH)
(Real Time Quote from BATS)
$27.40 USD
-0.17 (-0.62%)
Updated Jul 9, 2024 02:18 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Guardant Health (GH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$37.00 | $47.00 | $28.00 | 34.20% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Guardant Health comes to $37.00. The forecasts range from a low of $28.00 to a high of $47.00. The average price target represents an increase of 34.2% from the last closing price of $27.57.
Analyst Price Targets (19)
Broker Rating
Guardant Health currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.26 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.71% and 9.52% of all recommendations. A month ago, Strong Buy made up 80.95%, while Buy represented 9.52%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 17 | 16 | 15 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.26 | 1.27 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Guggenheim Securities | Subbu Nambi | Hold | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/24/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
5/24/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
5/13/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
5/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/29/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
4/24/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
4/15/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
2/26/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
1/12/2024 | UBS | Dan Leonard | Not Available | Strong Buy |
12/15/2023 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Hold |
9/28/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 21 |
Average Target Price | $37.00 |
LT Growth Rate | 32.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.57 |